SKVIOTCPharmaceutical PreparationsFiscal year ends December 31

SKINVISIBLE, INC.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$0.16+0.00 (+0.06%)

Close on Oct 19, 2026

Market cap: $843.54K
P/E (TTM): –
Dividend yield: –

Earnings

Quarterly results announced on Form 8-K, Item 2.02

No earnings releases found

Skinvisible has not filed an earnings release (Form 8-K, Item 2.02) that we could match to a fiscal quarter.

Press releases

Announcements Skinvisible filed with the SEC

Jan 23, 2025, 3:20 PM ET
PRESS RELEASE, DATED JANUARY 23, 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Oct 3, 2024, 11:21 AM ET
PRESS RELEASE, DATED OCTOBER 3, 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
May 29, 2024, 1:35 PM ET
PRESS RELEASE, DATED MAY 29, 2024
Regulation FD disclosure · EX-99.1 to Form 8-K

Where these numbers come from

Parsed from the XBRL in Skinvisible's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-50 reverse split on Apr 15, 2019
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SKVI.

Operating margin-2294.9% · median -9077.1%

Net margin-5156.6% · median -1149.5%

Company	Revenue	Growth
IBO	$35.00K	–
BDPT	$25.56K	+694.1%
SKVI	$20.00K	0.0%
KPRX	–	–
JUNS	–	–
AZTR	–	–

Company

Exchange: OTC
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 2
Auditor: GreenGrowth CPAs
SEC CIK: 1085277

Advertisement
300 × 250